Emphasising safety and sustainability in circular design A stronger focus on safety, health and sustainability is needed in designing circular products. When basic resources are re-used in new products, health risks should be avoided.
CleaR delivers framework for risk assessment of substances of concern in the recycling process For a successful circular economy, it is essential to improve the conditions in which materials and products are recycled once they have reached the end of their life cycle.
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).
WHO:RIVM Centre for Healthy Living a good practice for other countries According to the World Health Organization (WHO), the RIVM Centre for Healthy Living is a prime example of how the national government has taken up its stewardship role within the health promo
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
The Circular Economy: starting progress measurement in the Netherlands A new report by Statistics Netherlands (CBS), the Netherlands Environmental Assessment Agency (PBL) and RIVM outlines a draft monitoring system to measure progress throughout the planned trans
Promising biobased alternatives to controversial polar aprotic solvents There are a number of promising biobased alternatives to controversial polar aprotic solvents, as revealed in a report from Wageningen Food & Biobased Research commissioned by RIVM .
Substances of very high concern hamper recycling Substances of very high concern (SVHC) can hamper the safe recycling of waste streams in the Netherlands. These substances occur in a wide range of waste streams.
Risks of potential release of genetically modified mosquitoes evaluated On Saba, a Dutch Caribbean island, diseases such as dengue, chikungunya and zika can be reduced by the use of genetically modified mosquitoes.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.